Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial - Top-Institutions - MDSpire

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial

  • By

  • Priscilla Merriam

  • James J. Morrow

  • Emanuele Mazzola

  • Nicole L. Solimini

  • Prafulla C. Gokhale

  • Ping Chi

  • Alice P. Chen

  • Mark Agulnik

  • Melissa Burgess

  • Scott M. Schuetze

  • Neeta Somaiah

  • Brian A. Van Tine

  • Seth M. Pollack

  • Gabriel Tinoco

  • Jonathan Trent

  • Breelyn A. Wilky

  • Nicola Bothwick

  • Benjamin K. Eschle

  • Vivian Nguyen

  • Jan H. Beumer

  • Noushin Rastkari

  • Shahanawaz Jiwani

  • Peter I-Fan Wu

  • Lorraine Pelosof

  • Matthew L. Hemming

  • Geoffrey I. Shapiro

  • George Demetri

  • Bradley Bernstein

  • Suzanne George

  • May 26, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #2

    National Cancer Institute, NIH Clinical Center
    National Cancer Institute, NIH Clinical Center

    Bethesda, Maryland

    Key Differentiators

    • Oncology

  • #3

    Massachusetts General Hospital Cancer Center
    Massachusetts General Hospital Cancer Center

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #4

    Oregon Health & Science University
    Oregon Health & Science University

    Portland, Oregon

    Key Differentiators

    • Oncology

  • #5

    Yonsei University College of Medicine
    Yonsei University College of Medicine

    Seoul, South Korea

    Key Differentiators

    • Oncology

Original Source(s)

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial

  • by Priscilla Merriam, James J. Morrow, Emanuele Mazzola, Nicole L. Solimini, Prafulla C. Gokhale, Ping Chi, Alice P. Chen, Mark Agulnik, Melissa Burgess, Scott M. Schuetze, Neeta Somaiah, Brian A. Van Tine, Seth M. Pollack, Gabriel Tinoco, Jonathan Trent, Breelyn A. Wilky, Nicola Bothwick, Benjamin K. Eschle, Vivian Nguyen, Jan H. Beumer, Noushin Rastkari, Shahanawaz Jiwani, Peter I-Fan Wu, Lorraine Pelosof, Matthew L. Hemming, Geoffrey I. Shapiro, George Demetri, Bradley Bernstein, Suzanne George

  • May 26, 2026

Related Content

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report